Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted September 4, 2007
Avandia, data, and PR damage
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Member Program Contributor
-reassuring clinical data -severe PR damage
Posted September 3, 2007
Liraglutide, potenital, and barriers
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Member Program Contributor
-Key therapeutic class -difficult competition
Posted September 3, 2007
Mitiglinide—Thrice Your Out
Analysis of: Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA | www.pipelinereview.com
Author: GLG Member Program Contributor
Mitiglinide may have a role in specific subtypes of diabetes patients, but it thrice a day dosing in a hurdle for all but the compulsive few.
Posted September 3, 2007
Diabetes Medications Are For Sugars; Statins and Hypertensives Are For Hearts
Analysis of: FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals | www.medpagetoday.com
Author: GLG Member Program Contributor
To demand diabetes medications have positive outcomes would be akin to asking for proof that antibiotics save lives or statins lower blood sugars. If this be law, we would have very few drugs and lots of sick patients.
Posted August 29, 2007
Alternative medications available
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Member Program Contributor
With so many other medications available to help control diabetes, who will risk prescribing Avandia? 
Posted August 23, 2007
Better or different vs: Byetta?
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: GLG Member Program Contributor
GPL-1 analogs are really good drugs except for significant side effects. Will this drug be better than what we already have? What will be long term adherence?
Eric Gruff Posted August 23, 2007
"The Big GLP" - Should We Be Excited About Novo's Liraglutide?
Analysis of: Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients | www.pipelinereview.com
Author: Eric Gruff, Principal E4 Consulting
The results of two Phase III trials conducted by Novo Nordisk on liraglutide, a once-daily dosed GLP-1 analog, indicate significant glucose lowering efficacy and weight loss. On a positive note, Novo has to be relieved that they are seeing the same magnitude of HbA1c reduction and weight loss...
Posted August 21, 2007
GlaxoSmithKline adds a Black Box Warning for Avandia.
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Member Program Contributor
New black box warning for Avandia makes the warning for CHF risk stronger. The information about an increase in Coronary Ischemia events is not addressed by this change in labeling. Physicians wait for FDA to drop the other shoe.
Posted August 21, 2007
Avandia And The Story Of Humpty Dumpty
Analysis of: GlaxoSmithKline updates prescribing information for Avandia in the US | www.pipelinereview.com
Author: GLG Member Program Contributor
The Black Box CHF Warning for Avandia and Actos, is not new information. It merely defects the real issue-- the risk of overall cardiac events.
Posted August 20, 2007
SYMLIN-All this poken' could lead to one smoken'
Analysis of: SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes | www.pipelinereview.com
Author: GLG Member Program Contributor
Too much hastle for too little benefit
Previous Page : 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Next201 to 210 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353